Clinical Trials on Locally Advanced Vulvar Carcinoma in Canada

Total 165 results

University of Alberta

Withdrawn

Imaging of Advanced Tumours Using [131]I-IAZA

Locally Advanced Solid Tumors | Metastatic Solid Tumors

Canada
AHS Cancer Control Alberta
Cross Cancer Institute

Withdrawn

Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients

Metastatic Solid Malignancies | Locally Advanced Solid Malignancies

Canada
British Columbia Cancer Agency

Withdrawn

Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)

Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)

Canada
Spanish Oncology Genito-Urinary Group
Roche Pharma AG

Completed

Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma (AUREA)

Locally Advanced or Metastatic Urothelial Carcinoma

Spain
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

First in Human Study of M1069 in Advanced Solid Tumors

Metastatic or Locally Advanced Unresectable Solid Tumors

United States, Canada
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Hypopharyngeal Carcinoma AJCC v8 | Stage III Laryngeal Cancer AJCC v8 | Stage III Lip and Oral Cavity Cancer AJCC v8 | Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Stage IVA Lip and Oral... and other conditions

United States, Canada
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Study of M1774 in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

Metastatic or Locally Advanced Unresectable Solid Tumors

United States, Canada, Spain
Lawson Health Research Institute

Recruiting

Low-Dose Weekly vs High-Dose Cisplatin (RADIO)

Locally Advanced Head and Neck Squamous Cell Carcinoma

Canada
University Health Network, Toronto
Canadian Association of Radiation Oncology

Completed

Healthy Bones Study

Locally Advanced Malignant Neoplasm

Canada
National Cancer Institute (NCI)

Suspended

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

Locally Advanced Leiomyosarcoma | Metastatic Undifferentiated Pleomorphic Sarcoma | Locally Advanced Liposarcoma | Locally Advanced Undifferentiated Pleomorphic Sarcoma | Locally Advanced Extraskeletal Myxoid Chondrosarcoma | Locally Advanced Unresectable Soft Tissue Sarcoma

United States, Canada
British Columbia Cancer Agency
Canadian Cancer Trials Group; Australia New Zealand Gynaecological Oncology... and other collaborators

Not yet recruiting

STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide Excision (STRIVE)

Vulvar Cancer

Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection (GROINSS-V)

Stage III Vulvar Cancer | Vulvar Squamous Cell Carcinoma | Stage I Vulvar Cancer | Stage II Vulvar Cancer

United States, Canada
Nuvalent Inc.

Recruiting

A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

Metastatic Solid Tumor | Locally Advanced Solid Tumor

Canada, United States, Korea, Republic of, Taiwan, Spain, Australia, Belgium, France, Netherlands, Singapore, Germany
AstraZeneca

Active, not recruiting

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

Locally Advanced or Metastatic Solid Tumours

United States, Spain, Canada, Korea, Republic of
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics

Recruiting

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

Locally Advanced or Metastatic Urothelial Carcinoma

Korea, Republic of, United States, Taiwan, Australia, United Kingdom, France, Greece, Italy, Belgium, Spain, Canada, Denmark, Germany
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Spain, Taiwan, United Kingdom
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Korea, Republic of, China, Spain, Taiwan, Japan, Argentina, Canada, Croatia, Greece, Ireland, Malaysia, Netherlands, Portugal, Romania, Thailand, Turkey, United Kingdom
Gilead Sciences
Everest Medicines

Active, not recruiting

Study of Sacituzumab Govitecan-hziy (IMMU-132) Versus Treatment of Physician's Choice in Participants With Metastatic or Locally Advanced Unresectable Urothelial Cancer (TROPiCS-04)

Locally Advanced or Metastatic Unresectable Urothelial Cancer

United States, Belgium, France, Spain, United Kingdom, Korea, Republic of, Czechia, Germany, Israel, China, Italy, Australia, Hong Kong, Taiwan, Portugal, Singapore, Croatia, Greece, Turkey, Sweden, Switzerland, Canada, Austria, Bulgaria and more
Ontario Clinical Oncology Group (OCOG)
Juravinski Cancer Centre Foundation

Completed

A Prospective Study to Evaluate FDG-PET, Breast MRI, and Breast Ultrasonography in Monitoring Tumour Responses in Patients With Locally Advanced Breast Cancer (LABC) Undergoing Neoadjuvant Chemotherapy (PETLAB)

Locally Advanced Breast Cancer

Canada
AstraZeneca

Completed

Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours (CAURAL)

Locally Advanced or Metastatic EGFR T790M+ NSCLC

Canada, Korea, Republic of, Taiwan
Sunnybrook Health Sciences Centre

Completed

Dynamic Breast MRI in Assessing Locally Advanced Breast Cancer

Locally Advanced Breast Cancer

Canada
Genentech, Inc.

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced Solid Tumors | Metastatic Solid Tumors | Recurrent Solid Tumors

Australia, United States, Canada
Lawson Health Research Institute

Recruiting

Three Fraction Radiation to Induce Immuno-Oncologic Response (TRIO)

Locally Advanced Breast Cancer | High-Risk Cancer

Canada
University Health Network, Toronto

Completed

Using Bio Markers to Predict Disease Recurrence and Cognitive Function in High Risk Breast Ca (Cyto-Cog)

Breast Cancer | Locally Advanced Breast Cancer

Canada
Ontario Clinical Oncology Group (OCOG)

Completed

Blood Oxygen Level Dependent Magnetic Resonance Imaging (BOLD MRI) and Fluorothymidine Positron Emission Tomography (FLT PET) in Patients With Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy (IMPACT)

Locally Advanced Breast Cancer (LABC)

Canada
Bayer

Recruiting

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body (ON-TRK)

Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion

United States, Austria, Denmark, Germany, Italy, Norway, Spain, United Kingdom, Brazil, Russian Federation, Switzerland, Taiwan, Canada, China, Australia, Greece, Belgium, Sweden, Korea, Republic of, France, Argentina, Finland, Ireland and more
Spanish Breast Cancer Research Group
Seagen Inc.

Recruiting

Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer (TrasTUCAN)

HER2-positive Metastatic Breast Cancer | Locally Advanced HER2 Positive Breast Carcinoma

Spain
Ocellaris Pharma, Inc.

Recruiting

A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Sarcoma | Neoplasms | Renal Cell Carcinoma | Cervical Cancer | Cancer | Hepatocellular Carcinoma | Gastric Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Metastatic Cancer | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Triple Negative Breast Cancer | Urothelial Carcinoma | Merkel Cell Carcinoma | Squamous... and other conditions

Canada
Nanobiotix

Recruiting

NBTXR3 With or Without Cetuximab in LA-HNSCC

Aged | Locally Advanced Head and Neck Squamous Cell Carcinoma

France, Spain, Israel, United States, Taiwan, Finland, Japan, Belgium, Korea, Republic of, Hungary, China, Georgia, Portugal, Austria, Bulgaria, Canada, Czechia, Germany, Greece, Romania, Serbia
University Health Network, Toronto

Recruiting

FAZA PET/MRI Pancreas

Locally Advanced Pancreatic Adenocarcinoma | Unresectable Pancreatic Cancer | Pancreatic Adenocarcinoma Non-resectable

Canada
AstraZeneca

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)

Locally Advanced Head and Neck Squamous Cell Carcinoma

United States, Spain, Italy, Canada, Korea, Republic of, United Kingdom, Germany, Vietnam, Japan, France, India, Taiwan, Thailand, Malaysia, Turkey, Brazil, Belgium, Poland, Austria, Hungary
Dr. Danielle Vicus

Recruiting

Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer. (Vulvar-AIN)

Cervical Cancer | Vulvar Cancer | Anal Cancer | Cervical Dysplasia | HPV-Related Anal Squamous Cell Carcinoma | Anal Dysplasia | Vulvar Dysplasia

Canada
National Cancer Institute (NCI)

Active, not recruiting

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Unresectable Breast Carcinoma | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma

United States, Canada
National Cancer Institute (NCI)

Recruiting

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Unresectable Pancreatic Carcinoma | Locally Advanced Pancreatic Carcinoma

United States, Canada
Rainier Therapeutics

Terminated

Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma (FIERCE-21)

Urinary Bladder Disease | Locally Advanced or Metastatic Urothelial Cell Carcinoma | Urological Diseases

Italy, Spain, United States, Korea, Republic of, Turkey, Taiwan, Sweden, Czechia, United Kingdom
Nuvalent Inc.

Recruiting

A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Metastatic Solid Tumor | Locally Advanced Solid Tumor

United States, Australia, Taiwan, Spain, United Kingdom, France, Korea, Republic of, Canada, Singapore
Radiation Therapy Oncology Group
GlaxoSmithKline; Novartis

Completed

TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer. (TRYHARD)

Non-HPV Locally Advanced Head and Neck Cancer

United States, Canada
Hoffmann-La Roche

Terminated

A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States, Korea, Republic of, Canada, Australia, Russian Federation, United Kingdom, Belgium, Brazil, China, France, Italy, Portugal, Spain, Japan, India, Thailand, Ukraine, Taiwan, Poland, Turkey, Hungary, South Africa, Germany
University Health Network, Toronto
AstraZeneca; NeoGenomics Laboratories

Recruiting

Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC (MERIDIAN)

Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

Canada
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

United States, Spain, Italy, Australia, Russian Federation, Taiwan, Korea, Republic of, Thailand, Canada, Turkey, Germany, Romania, United Kingdom, Hungary, Brazil, France, Japan
Takeda
Takeda Development Center Americas, Inc.

Recruiting

First-in-Human Study of TAK-280 in Participants With Unresectable Locally Advanced or Metastatic Cancer

Unresectable Locally Advanced or Metastatic Cancer

Spain, United States, Australia, Canada
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Cervical Cancer | Small Cell Lung Carcinoma | Neuroendocrine Tumor | Advanced Solid Tumors | Mesothelioma | Vulvar Cancer | Cholangiocarcinoma | Bile Duct Cancer | Endometrial Cancer | Advanced Cancer | Cervical Carcinoma | Endometrial Carcinoma | Thyroid Carcinoma | Thyroid Cancer | Anal Cancer | Colorectal Carcinoma | Carcinoid... and other conditions

Canada, France, Germany, Italy, Mexico, Netherlands, Poland, Russian Federation, Taiwan, United States, Brazil, Colombia, Israel, Korea, Republic of, Norway, Philippines, South Africa, Spain, Australia, Denmark, Chile, Portugal, Peru
University Health Network, Toronto
Princess Margaret Hospital, Canada

Completed

Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN)

Head and Neck Cancer | Metastatic Cancer | Advanced Cancer | HNSCC | Squamous Cell Carcinoma

Canada
AHS Cancer Control Alberta

Not yet recruiting

Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo) (IMPACT 1)

Diarrhea | Advanced Melanoma | Immune-related Adverse Event | Advanced Rectal Carcinoma

Canada
University Health Network, Toronto

Completed

Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma (ROMA LA-OPSCC)

Locoregionally-advanced Oropharyngeal Squamous Cell Carcinoma

Canada
University Health Network, Toronto
Novartis Pharmaceuticals

Completed

Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer

Squamous Cell Carcinoma of Head and Neck | Locoregionally Advanced

Canada
AstraZeneca

Active, not recruiting

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (NILE)

Metastatic Urothelial Cancer | Unresectable Locally Advanced Urothelial Cancer

United States, Italy, Spain, Canada, Hungary, Poland, Argentina, Thailand, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, India, Japan, Philippines, Russian Federation, China, Taiwan, Israel, Australia, Bulgaria
John Lenehan

Not yet recruiting

CHemotherapy And Stool Transplant in PDAC (CHASe-PDAC) (CHASe-PDAC)

Unresectable or Metastatic Advanced Pancreatic Ductal Adenocarcinoma

Canada
Spanish Breast Cancer Research Group
AstraZeneca

Recruiting

Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab (TRANSCENDER)

Metastatic Breast Cancer | Locally Advanced Breast Cancer

Spain
AstraZeneca
Parexel

Completed

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib (ELIOS)

EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Spain, United States, Italy, Korea, Republic of, Malaysia

Clinical Trials on Locally Advanced Vulvar Carcinoma in Canada

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations